In this introduction we briefly review the literature on intellectual property rights and access to medicines, identifying two distinct generations of research. The first generation analyzes the origins of new intellectual property rules, in particular the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), and the significance of TRIPS to developing countries. The second generation examines national-level experiences, as countries adjust their laws and practices to conform to TRIPS.
Introduction
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Global changes have national consequences. Changes in international rules affect national policies and practices, which in turn affect the people's lives and livelihood. This special issue addresses these relationships by examining how changes in the rules of the international trade system can affect national development policies that bear on health.
International trade rules may bear on health through a complex causal chain linking access to health to access to medicines, access to medicines to price of drugs, and price of drugs to intellectual property (IP) protection. The World Health Organization (WHO) estimates that one-third of the people living in developing countries are unable to receive or purchase essential medicines on a regular basis. 2 In pursuit of better health care outcomes, one of the many challenges governments face is improving access to medicines. And the price of drugs, in turn, can create challenges for improving access to medicines. While health, access to medicines, and the price of drugs are, of course, a function of many factors, one important issue regards the role of intellectual property (IP). Where pharmaceutical firms have patents on drugs, they can, potentially, limit the competition they face and raise the price of drugs.
This causal chain linking IP to health has become increasingly important and received a great deal of attention on account of major changes at the global level that mark the start of the 21 st Century. Specifically, when the World Trade Organization (WTO) was founded in 1 The special issue is a result of two workshops hosted by the Watson Institute for International Studies, Brown University. The first, on "Global Governance and Civil Society," took place in October 2012; the second, on "Access to Medicines in the Global South," took place in January 2014. We would like to thank Peter Evans for suggesting and co-organizing the workshops, and for his continuous support throughout this process. We would also like to thank Barbara Stallings for her support and guidance in bringing the collection of papers together in this special issue of the journal. Matthew Flynn, Anne Roemer-Mahler, Valbona Muzaka, and two anonymous reviewers provided invaluable comments on this introduction, for which we are grateful. TRIPS fundamentally reshaped the debate over access to medicines. Prior to TRIPS, countries had significant autonomy in designing and implementing their IP policies.
Concerned about the effects that IP in pharmaceuticals might have on the price of drugs and health, for example, many countries did not allow patents in this area. 3 TRIPS requires all countries to grant pharmaceutical patents. The extension of the international patent system to mandate coverage of pharmaceuticals, a major and unprecedented shift, has sparked widespread interest and concern over what impact it would have on access to medicines, especially in countries with limited resources. associations from pharmaceuticals (and other IP-sensitive sectors) that sought greater protection on a global scale.
5
The results of these efforts include TRIPS, of course, but more generally the prominent place that IP plays in the foreign economic policies of the world's leading powers.
After all, TRIPS is hardly the only international agreement on IP that affects developing countries -it is not even the only "trade-related" international agreement on IP that affects developing countries. Complementing and building on the research on international IP rules and their implications, a second generation of research examined national-level implementation and the "on the ground" effects of these grand changes. Here, analytic attention shifts from the constraints that the global political economy presents to the actions taken by countries in response. This is a natural progression. After carefully analyzing the processes by which new 8 Countries that did not grant pharmaceutical patents as of the start of TRIPS had until 2005 to do so. Countries varied in how much of this transition period they utilized. 9 We refer here to the "Decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health," adopted in August 2003. For analyses of these events, see, among others, Chorev (2012), Shadlen (2004) , Abbott and Reichman (2007) .
international rules were created, it is logical for scholars to examine how and the extent to which these were implemented at the national level, especially given the built-in flexibilities in the international agreement.
The literature on TRIPS implementation includes a proliferation of case studies, both single-country and cross-national, providing fresh observations of what is happening on the ground in various parts of the world. We do not purport to review this whole body of works here, rather we wish to point to some of the various explanatory factors that have been Thus, in contributing to this second generation of scholarship on IP, and access to medicines, and health, the special issue provides fresh theoretical and empirical insights that contribute to our understanding of the politics of global policies more broadly.
The remainder of this introductory chapter consists of three sections. We begin by discussing the principal insights that the authors bring with regard to IP policymaking, TRIPS implementation, and the use of flexibilities. We then discuss their analyses with regard to the effects of policy measures taken. In the final section we offer brief summaries of each article in the special issue.
Using Flexibilities: Rethinking Conditions and Strategies
Implicit in the first generation of research is an expectation that, were the international context less restrictive, countries would utilize more creative policies and take advantage of Thus, while international politics certainly play an important role, the analyses in this collection point to the domestic political challenges to utilizing TRIPS flexibilities. In particular, the articles suggest that alliances and coalitions are necessary to underpin the use of flexibilities, and these are difficult to construct and sustain. Our point here is not to debate this causal logic; few would dispute that the path to access to medicines passes through IP, nor would many disagree that more than IP alone affects access to medicines. Our point, rather, is to show how this orientation and emphasis can affect the process of alliance formation in domestic settings. The challenge is that while local health activists may share global activists' goal of improving access to affordable and high-quality medicines, they may embrace different approaches and strategies to achieve that goal. For example, local health activists may prioritize lowering prices, which they may believe can be accomplished without the explicit use of IP flexibilities, or they may regard the quality and state of countries' health care systems as more essential for improving access to medicines than utilizing flexibilities and relaxing levels of patent protection. In some cases, local activists may not even share the concern with improving access to medicines. As Godoy shows, in Costa Rica, El Salvador, and Guatemala, activists with a different approach to health came to resent -or at least greet with caution -the global activists' IP-oriented approach. Local activists feared that a focus on TRIPS flexibilities placed too much trust in the efficiency of market competition, could lead to an overly industrial-biomedical "pharmaceuticalization" approach to health, and would likely undermine the basic health care approach they preferred.
Why this gap between global and local approaches? It is not difficult to understand global activists' emphasis on IP. More than many public health initiatives, ideas about the IPaccess-health link are easier to diffuse across international boundaries and seem easier to implement. They are easy to diffuse because they draw on an accessible message that effectively creates "villains" in the form of multinational pharmaceutical companies oblivious to nothing but their profits. They are easy to diffuse also because of the promise of the relative simplicity of implementation. After all, IP changes seem to only require a legislative act, in contrast to initiatives that may also require resources, the presence of competent bureaucrats, skilled health workers, or improvements to health care infrastructure. IP policy changes also tend to be discrete events. Actors focus on specific elements of a country's IP law to change, legislators make changes, and when the law is changed it is difficult (though certainly not impossible) to reverse. Alternative measures, such as reforms to healthcare systems, in contrast, involve multiple parts that need to be coordinated and more likely require significant follow-up. Initiatives such as the development of local pharmaceutical production might be even more challenging, as shown by Russo and Banda. The point, then, is that alliances between global and local health activists may be unstable, not because of the former's naivety about what is happening on the ground or the latter's indifference to IP, but simply because of a set of factors that may drive both sets of actors to prioritize different sets of issues. In short, alliances between global and local activists -two sets of actors that both care about health -may be anything but naturally occurring outcomes. Rather, they need to be established and, at times, they may fail to materialize due to distinct interests, priorities, and strategies.
Our papers also suggest that there may be geographical and temporal patterns to the likelihood of alliances between global and local activists. Andia's article hints at the possibility that such alliances are more likely to happen in countries that are "trend setters,"
where local activists recruit global activists, than among the countries that are followers, where global activists recruit local participants. Chorev, in turn, suggests the possibility of a diminishing interest of civil society in IP issues, especially as conflicts become more arcane and difficult to comprehend, as was the case with the Anti-Counterfeit Act in Kenya. Although it is beyond the scope of their papers, it is also easy to imagine that the laws governing secondary patenting in Brazil and India, studied by Sampat and Shadlen, have been influenced by the interplay between global and local forces; similarly, the industrial policies affecting local pharmaceutical production, the subject of Russo and Banda's piece, may be influenced by the support (or lack thereof) of local health activists. The punchline is that the support of local activists is important at the level of policy-making, but possibly even more so at the stage of implementation. As Godoy suggests, "the transnational gaze is always fleeting; ultimately, unless local activists take up an issue, any gains made during the period of the transnational campaigning may be short-lived."
These observations mean that we need to be much more attentive not only the localspecific interests of the many actors involved in making and implementing policies in any given setting, but also to the specific political economic contexts in which activists and other relevant actors function, for it is these contexts that will shape actors' position and the possibility of alliances. Much of the scholarship treats the politics of IP as if it were a universe of its own, as if the conflicts over different aspects of IP policy (international, regional, national) occurred in a silo. But IP is always a part of broader set of issues, part of a broader political economy. Indeed, this is one of the first lessons of the early research reviewed above: IP was made "trade-related" and thus addressed in the context of trade
negotiations. Yet subsequent discussion has had a tendency to focus on IP on its own terms.
Consider, for example, the abundant literature on IP in regional and bilateral trade agreements, referred to above. We know that regional and bilateral trade agreements typically include IP provisions that, because they exceed those in the WTO, are typically regarded with
alarm. Yet these agreements are about much more than IP. What much of this work seems to overlook is that "TRIPS Plus" trade agreements also include benefits, in terms of enhanced market access for non-traditional exports, which also exceed what is available in the WTO (Shadlen 2005). That is not to say that the agreements, on the net, are "good" (i.e. that the benefits for developing countries outweigh the costs), but simply to draw our attention to the fact that agreements of this sort are founded on trade-offs. In the context of making trade-offs the actors opposed to the IP provisions may prevail, or their concerns may get subordinated.
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It is incumbent on political analyses to understand how actors concerned with IP interact with other actors with different concerns.
Broadening the analytic lens to look beyond IP per se is useful for consideration of domestic laws too. After all, the Anti-Counterfeit Act in Kenya, for example, was concerned with many more commodities and products than medicines, which necessarily affected the support and opposition to it in Parliament as well as civil society. Grounding the analysis of IP in this way, we believe, will not only allow us to better understand actors' positions, actions and possible successes in the struggles over intellectual property rights, but will also improve dialogue between scholars of IP and scholars of international political economy and development. While IPE and development scholarship provide useful analytical tools for sharpening the analysis of IP; the empirically rich IP scholarship is a particularly fertile ground for applying and development new arguments and theories relevant for IPE and development.
Using Flexibilities: Rethinking the Effects
In spite of the challenges to building and sustaining alliances, many countries have taken steps to utilize TRIPS flexibilities and resisted attempts to curtail the use of flexibilities. Many countries now have laws that permit and facilitate compulsory licensing, for example, or that place restrictions on secondary patenting. Indeed, many "TRIPS Plus"
provisions have been relaxed, as many of the articles in this special issue illustrate. However, these articles also suggest that, even when all the pieces are lined up and the alliances come together, the implementation of TRIPS flexibilities may not have the desired outcomes.
Andia finds that even though in both Colombia and Ecuador compulsory licensing was permitted by law, and in Ecuador a compulsory license was issued, both countries continued to purchase the patented version of the drug Kaletra, rather than generic versions. Moreover, Andia argues that the compulsory licenses themselves cannot explain the price reductions that these countries secured. Sampat and Shadlen's analysis of secondary patenting in Brazil and
India also forces us to think about how effective touted TRIPS flexibilities may be in practice. Both countries' patent laws include provisions that could potentially minimize secondary patenting, but these authors find that India has a surprisingly low rejection rate of secondary patents, and that where applications for secondary patents are rejected, rarely is this directly attributable to the specific mechanisms in place to achieve this goal. The grant rate for secondary patents appears to be lower in Brazil, but, again, the direct effects of the specific measure put in place to achieve this goal are less than one might expect.
One reason for this gap between intentions and outcomes, of course, is the complexity involved in improving access to medicines and health. As discussed above, these outcomes are affected by myriad factors, so that even successfully implemented TRIPS flexibilities may have only marginal effects on overall outcomes. Even if we look not at the overall goal of improved access to drugs but the more immediate goals, such as lowering the price of a particular drug or the rate of secondary patenting, complexity may contribute to the minimal impacts these studies report. But they may not. These articles offer two ways of thinking about the gap between the outcomes intended by policy changes and the actual outcomes yielded by policy changes.
One possible interpretation offered here is that TRIPS flexibilities may not yield the benefits that are expected because they are challenging to implement and enforce. This view is consistent with a long tradition of scholarship. We know from the distinction between "law in books" and "law in action" and from the institutional analysis of policy-making that new laws do not often bring about the intended outcomes. Laws create opportunities; they set boundaries of permissible and non-permissible action. But opportunities need to be seized;
and sometimes actors expected to seize opportunities for action lack the interests for doing so, or the necessary resources for doing so; or actors who would be disadvantaged by the enforcement of a law counter-mobilize. In such cases, we should indeed expect to witness gaps between the outputs that laws allow and the outputs that we observe.
A second interpretation, also offered here, is that "counter-hegemonic globalization" Pharmaceutical markets and health care systems are likely to operate differentlyfundamentally differently -in a world marked by TRIPS, with pharmaceutical patents, even if countries actively used their flexibilities in terms of restricting the grant of some patents, threatening and issuing compulsory licenses, allowing parallel imports, embarking on local production, and so on. The world has changed, and the use of flexibilities cannot restore the pre-TRIPS order. Chorev's article speaks clearly and explicitly to this issue: over time, the stakes become smaller. This means that the potential achievements of some legal changes are small. If the room for dispute has narrowed, then we need to reconsider our expectations of just how much significant change on the ground we should expect to observe as a result of policy reforms.
Summary of papers
The authors contributing to this special issue are all concerned with the question of access to medicines, but draw on different case studies and come to distinct conclusions.
Chorev is interested in the trajectory leading from one IP-related dispute to another.
She studies the struggles over the legislation of two laws in Kenya, the Industrial Property Act, 2001, which included a number of important flexibilities and was as a result supported by health activists, and the Anti-Counterfeit Act, 2008, which, activists argued, threatened some of the flexibilities gained in the Industrial Property Act. Looking at the debates over each law, the paper argues that, contrary to the activists' claims, the stakes of the second dispute were much lower -indeed, secondary -than the stakes in the earlier dispute. The paper argues that this is typical to international disputes and explains why that is the case.
Godoy explains why transnational health activists were not able to successfully mobilize local activists in Central America against the escalation of IP requirements in the context of CAFTA's ratification debates. The article spells out the tension between the considerations and interests motivating the agenda of global activists, local health activists, and local pharmaceutical producers. The analysis situates local actors within the specific political and economic contexts, identifying, rather than assuming, these actors' goals and strategies. In doing so Godoy reveals the potential mismatches between with the goals and strategies of the various actors involved in the political economy of pharmaceutical IP in Central America.
Andia is interested not only in the political processes leading to the introduction of flexibilities (compulsory licensing) in various countries, but in the political processes affecting the utility of the policies once in place. Comparing price reductions of the brandname antiretroviral drug Kaletra in Colombia and Ecuador, Andia also emphasizes the tensions between global and local activists in policy formation. Yet Andia also shows that the extent to which local actors are invested in a law influences its successful implementation even more so than its enactment.
Sampat and Shadlen use original datasets of governments' decisions regarding secondary patenting to assess the effects of flexibilities on access to medicines. Their analyses of pharmaceutical patent examination in Brazil and India offer comparisons of the distinct filing and examination patterns in these countries, placing the countries' practices with regard to secondary patents in the context of their larger trajectories of TRIPS implementation. They find that, in both countries, the effects of the measures to address secondary patenting were outshadowed by the effects of earlier choices regarding the introduction of pharmaceutical patents in the first place.
In the final paper, Russo and Banda explore another aspect of access to medicinesthe local manufacturing of drugs. They describe the opportunities and obstacles of drug manufacturing in Mozambique and Zimbabwe and assess how political-economic conditions
